193 related articles for article (PubMed ID: 34951993)
1. Molecular Signature Predictive of Long-Term Liver Fibrosis Progression to Inform Antifibrotic Drug Development.
Qian T; Fujiwara N; Koneru B; Ono A; Kubota N; Jajoriya AK; Tung MG; Crouchet E; Song WM; Marquez CA; Panda G; Hoshida A; Raman I; Li QZ; Lewis C; Yopp A; Rich NE; Singal AG; Nakagawa S; Goossens N; Higashi T; Koh AP; Bian CB; Hoshida H; Tabrizian P; Gunasekaran G; Florman S; Schwarz ME; Hiotis SP; Nakahara T; Aikata H; Murakami E; Beppu T; Baba H; Rew Warren ; Bhatia S; Kobayashi M; Kumada H; Fobar AJ; Parikh ND; Marrero JA; Rwema SH; Nair V; Patel M; Kim-Schulze S; Corey K; O'Leary JG; Klintmalm GB; Thomas DL; Dibas M; Rodriguez G; Zhang B; Friedman SL; Baumert TF; Fuchs BC; Chayama K; Zhu S; Chung RT; Hoshida Y
Gastroenterology; 2022 Apr; 162(4):1210-1225. PubMed ID: 34951993
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design.
Friedman S; Sanyal A; Goodman Z; Lefebvre E; Gottwald M; Fischer L; Ratziu V
Contemp Clin Trials; 2016 Mar; 47():356-65. PubMed ID: 26944023
[TBL] [Abstract][Full Text] [Related]
3. Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study.
Ratziu V; Sanyal A; Harrison SA; Wong VW; Francque S; Goodman Z; Aithal GP; Kowdley KV; Seyedkazemi S; Fischer L; Loomba R; Abdelmalek MF; Tacke F
Hepatology; 2020 Sep; 72(3):892-905. PubMed ID: 31943293
[TBL] [Abstract][Full Text] [Related]
4. Quantifying and monitoring fibrosis in non-alcoholic fatty liver disease using dual-photon microscopy.
Wang Y; Wong GL; He FP; Sun J; Chan AW; Yang J; Shu SS; Liang X; Tse YK; Fan XT; Hou J; Chan HL; Wong VW
Gut; 2020 Jun; 69(6):1116-1126. PubMed ID: 31563875
[TBL] [Abstract][Full Text] [Related]
5. Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis.
Tacke F
Expert Opin Investig Drugs; 2018 Mar; 27(3):301-311. PubMed ID: 29448843
[TBL] [Abstract][Full Text] [Related]
6. Dual-photon microscopy-based quantitation of fibrosis-related parameters (q-FP) to model disease progression in steatohepatitis.
Wang Y; Vincent R; Yang J; Asgharpour A; Liang X; Idowu MO; Contos MJ; Daitya K; Siddiqui MS; Mirshahi F; Sanyal AJ
Hepatology; 2017 Jun; 65(6):1891-1903. PubMed ID: 28133774
[TBL] [Abstract][Full Text] [Related]
7. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.
Vilar-Gomez E; Calzadilla-Bertot L; Wai-Sun Wong V; Castellanos M; Aller-de la Fuente R; Metwally M; Eslam M; Gonzalez-Fabian L; Alvarez-Quiñones Sanz M; Conde-Martin AF; De Boer B; McLeod D; Hung Chan AW; Chalasani N; George J; Adams LA; Romero-Gomez M
Gastroenterology; 2018 Aug; 155(2):443-457.e17. PubMed ID: 29733831
[TBL] [Abstract][Full Text] [Related]
8. Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis.
Lambrecht J; van Grunsven LA; Tacke F
Expert Opin Pharmacother; 2020 Sep; 21(13):1637-1650. PubMed ID: 32543284
[TBL] [Abstract][Full Text] [Related]
9. Role of cenicriviroc in the management of nonalcoholic fatty liver disease.
Neokosmidis G; Tziomalos K
World J Gastroenterol; 2018 Dec; 24(48):5415-5417. PubMed ID: 30622370
[TBL] [Abstract][Full Text] [Related]
10. A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study.
Harrison SA; Ratziu V; Boursier J; Francque S; Bedossa P; Majd Z; Cordonnier G; Sudrik FB; Darteil R; Liebe R; Magnanensi J; Hajji Y; Brozek J; Roudot A; Staels B; Hum DW; Megnien SJ; Hosmane S; Dam N; Chaumat P; Hanf R; Anstee QM; Sanyal AJ
Lancet Gastroenterol Hepatol; 2020 Nov; 5(11):970-985. PubMed ID: 32763196
[TBL] [Abstract][Full Text] [Related]
11. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials.
Harrison SA; Wong VW; Okanoue T; Bzowej N; Vuppalanchi R; Younes Z; Kohli A; Sarin S; Caldwell SH; Alkhouri N; Shiffman ML; Camargo M; Li G; Kersey K; Jia C; Zhu Y; Djedjos CS; Subramanian GM; Myers RP; Gunn N; Sheikh A; Anstee QM; Romero-Gomez M; Trauner M; Goodman Z; Lawitz EJ; Younossi Z;
J Hepatol; 2020 Jul; 73(1):26-39. PubMed ID: 32147362
[TBL] [Abstract][Full Text] [Related]
12. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.
Friedman SL; Ratziu V; Harrison SA; Abdelmalek MF; Aithal GP; Caballeria J; Francque S; Farrell G; Kowdley KV; Craxi A; Simon K; Fischer L; Melchor-Khan L; Vest J; Wiens BL; Vig P; Seyedkazemi S; Goodman Z; Wong VW; Loomba R; Tacke F; Sanyal A; Lefebvre E
Hepatology; 2018 May; 67(5):1754-1767. PubMed ID: 28833331
[TBL] [Abstract][Full Text] [Related]
13. ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD.
Corey KE; Pitts R; Lai M; Loureiro J; Masia R; Osganian SA; Gustafson JL; Hutter MM; Gee DW; Meireles OR; Witkowski ER; Richards SM; Jacob J; Finkel N; Ngo D; Wang TJ; Gerszten RE; Ukomadu C; Jennings LL
J Hepatol; 2022 Jan; 76(1):25-33. PubMed ID: 34600973
[TBL] [Abstract][Full Text] [Related]
14. FibroGENE: A gene-based model for staging liver fibrosis.
Eslam M; Hashem AM; Romero-Gomez M; Berg T; Dore GJ; Mangia A; Chan HLY; Irving WL; Sheridan D; Abate ML; Adams LA; Weltman M; Bugianesi E; Spengler U; Shaker O; Fischer J; Mollison L; Cheng W; Nattermann J; Riordan S; Miele L; Kelaeng KS; Ampuero J; Ahlenstiel G; McLeod D; Powell E; Liddle C; Douglas MW; Booth DR; George J;
J Hepatol; 2016 Feb; 64(2):390-398. PubMed ID: 26592354
[TBL] [Abstract][Full Text] [Related]
15. Hepatic FATP5 expression is associated with histological progression and loss of hepatic fat in NAFLD patients.
Enooku K; Tsutsumi T; Kondo M; Fujiwara N; Sasako T; Shibahara J; Kado A; Okushin K; Fujinaga H; Nakagomi R; Minami T; Sato M; Uchino K; Nakagawa H; Kondo Y; Asaoka Y; Tateishi R; Ueki K; Ikeda H; Yoshida H; Moriya K; Yotsuyanagi H; Kadowaki T; Koike K
J Gastroenterol; 2020 Feb; 55(2):227-243. PubMed ID: 31602526
[TBL] [Abstract][Full Text] [Related]
16. ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver-Related Cirrhosis.
Calzadilla-Bertot L; Vilar-Gomez E; Wong VW; Romero-Gomez M; Aller-de la Fuente R; Wong GL; Castellanos M; Eslam M; Desai AP; Jeffrey GP; George J; Chalasani N; Adams LA
Hepatology; 2021 Jun; 73(6):2238-2250. PubMed ID: 32978796
[TBL] [Abstract][Full Text] [Related]
17. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A;
Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076
[TBL] [Abstract][Full Text] [Related]
18. Repeated measurements of non-invasive fibrosis tests to monitor the progression of non-alcoholic fatty liver disease: A long-term follow-up study.
Balkhed W; Åberg FO; Nasr P; Ekstedt M; Kechagias S
Liver Int; 2022 Jul; 42(7):1545-1556. PubMed ID: 35319156
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial.
Pedrosa M; Seyedkazemi S; Francque S; Sanyal A; Rinella M; Charlton M; Loomba R; Ratziu V; Kochuparampil J; Fischer L; Vaidyanathan S; Anstee QM
Contemp Clin Trials; 2020 Jan; 88():105889. PubMed ID: 31731005
[TBL] [Abstract][Full Text] [Related]
20. The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials.
Sanyal AJ; Harrison SA; Ratziu V; Abdelmalek MF; Diehl AM; Caldwell S; Shiffman ML; Aguilar Schall R; Jia C; McColgan B; Djedjos CS; McHutchison JG; Subramanian GM; Myers RP; Younossi Z; Muir AJ; Afdhal NH; Bosch J; Goodman Z
Hepatology; 2019 Dec; 70(6):1913-1927. PubMed ID: 30993748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]